PMAM
MDGL icon

Picton Mahoney Asset Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Picton Mahoney Asset Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-11,215
Closed -$728K – 714
2022
Q3 		$728K Buy
+11,215
New +$779K 0.03% 465

Other funds holding MDGL

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Picton Mahoney Asset Management's MDGL Position: Q4 2022 in Review

Picton Mahoney Asset Management sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2022, closing a stake of 11,215 shares — an estimated $728K sold.

Picton Mahoney Asset Management first reported a position in MDGL in Q3 2022 and held it in 1 quarter. The position peaked at $728K in Q3 2022. 189 funds tracked by Wall St. Rank hold MDGL as of Q4 2022.

  • Picton Mahoney Asset Management reported no remaining Madrigal Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Picton Mahoney Asset Management sold 11,215 Madrigal Pharmaceuticals shares in Q4 2022, an estimated $728K.
  • Picton Mahoney Asset Management first reported a position in Madrigal Pharmaceuticals in Q3 2022 and held it in 1 quarter.
  • Picton Mahoney Asset Management's Madrigal Pharmaceuticals position peaked at $728K in Q3 2022.
  • 189 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2022.

Based on Picton Mahoney Asset Management's 13F filing for Q4 2022, filed 13 Feb 2023.